Dinse Hannah, Skoda Eva-Maria, Schweda Adam, Jansen Christoph, Schmidt Kira, Konik Margarethe, Rohn Hana, Witzke Oliver, Stettner Mark, Kleinschnitz Christoph, Bäuerle Alexander, Teufel Martin
Clinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.
Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, Hufelandstrasse 55, Essen, 45147, Germany.
Trials. 2025 Apr 25;26(1):140. doi: 10.1186/s13063-025-08842-6.
A high number of individuals report suffering from physical and psychological sequelae symptoms after COVID-19-the so-called post COVID-19 condition. Commonly reported complaints include physical symptoms such as fatigue, headache, attention and concentration deficits or dyspnea and anxiety, symptoms of post-traumatic stress, or depression. Evidence-based treatment recommendations are still lacking up to this point. Associations between physical and psychological symptoms in chronic diseases are known for a long time. Support in coping with the disease and improvement of self-efficacy can have a positive effect on the course of diseases. For this reason, we designed a randomized, controlled explorative intervention trial as a treatment of bodily distress disorder in COVID-19 recovered persons.
Patients with a post COVID-19 condition meeting to the criteria of the WHO, along with a bodily distress disorder, are randomized in an intervention and control arm (TAU). Randomization takes place after a diagnostic interview, screening, and informed consent. In total, 60 patients will be included in the trial (30 per group). The intervention group receives a cognitive behavioral therapy as a video-conference-based group therapy (6 weeks) and mobile, respiratory biofeedback treatment (for 4 weeks). At several time points, both groups are assessed in terms of psychological and physical health status, treatment expectation, and satisfaction with the intervention. Furthermore, they will get biofeedback examination appointments. The primary outcome is the change in self-efficacy; secondary outcomes include assessed parameters of mental health, somatic symptoms, and satisfaction with the intervention. Data will be analyzed primarily using R and SPSS.
The randomized, controlled, explorative intervention trial POSITIV is one of the very first interventions for patients with post COVID-19 condition and psychological burden due to their different symptoms. The aim of the study is to generate new evidence and help patients to cope with the disease and thus, increase their quality of life and reduce symptomatology. We expect with a high probability that the patients' self-efficacy and health status will improve as a result of the intervention.
German Clinical Trial Register (DRKS); DRKS-ID: DRKS00030565. Registered on December 22, 2022.
大量个体报告称在感染新冠病毒后出现身体和心理后遗症症状,即所谓的新冠后状况。常见的症状包括疲劳、头痛、注意力和专注力缺陷、呼吸困难、焦虑、创伤后应激症状或抑郁等身体症状。截至目前,仍缺乏基于证据的治疗建议。慢性病中身体和心理症状之间的关联早已为人所知。在应对疾病方面提供支持并提高自我效能感可对疾病进程产生积极影响。因此,我们设计了一项随机对照探索性干预试验,作为对新冠康复者身体困扰障碍的一种治疗方法。
符合世界卫生组织标准且患有身体困扰障碍的新冠后状况患者被随机分为干预组和对照组(常规治疗)。在进行诊断性访谈、筛查并获得知情同意后进行随机分组。该试验共纳入60名患者(每组30名)。干预组接受基于视频会议的团体认知行为疗法(为期6周)和移动呼吸生物反馈治疗(为期4周)。在几个时间点,对两组的心理和身体健康状况、治疗期望以及对干预措施的满意度进行评估。此外,他们将获得生物反馈检查预约。主要结局是自我效能感的变化;次要结局包括心理健康、躯体症状的评估参数以及对干预措施的满意度。数据将主要使用R和SPSS进行分析。
随机对照探索性干预试验POSITIV是首批针对因症状不同而患有新冠后状况和心理负担的患者开展的干预措施之一。该研究的目的是产生新的证据,帮助患者应对疾病,从而提高他们的生活质量并减轻症状。我们极有可能预期干预措施会使患者的自我效能感和健康状况得到改善。
德国临床试验注册中心(DRKS);DRKS编号:DRKS00030565。于2022年12月22日注册。